Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06030258
Other study ID # IN10018-019
Secondary ID
Status Recruiting
Phase Phase 1/Phase 2
First received
Last updated
Start date October 30, 2023
Est. completion date October 21, 2025

Study information

Verified date August 2023
Source InxMed (Shanghai) Co., Ltd.
Contact Shu Fang
Phone 86-15933968623
Email shu.fang@inxmed.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a multicenter, open-label, Randomized, phase Ib/II clinical study to evaluate the anti-tumor efficacy, safety, tolerability, and PK of IN10018 in combination with anti-PD-1/L1 monoclonal antibody (Tislelizumab is proposed as the combination drug) and chemotherapy (platinum and etoposide) as the first-line treatment in Extensive-stage small cell lung cancer (ES-SCLC).


Description:

This study consists of 2 parts: 1) Phase Ib-Dose Confirmation part: To assess the PK parameters, safety and recommended phase II dose (RP2D) of IN10018 in combination with anti-PD-1/L1 monoclonal antibody (Tislelizumab is proposed as the combination drug), platinum (carboplatin is proposed as the combination drug) and etoposide as the first-line treatment in ES-SCLC. 2) Phase II-Dose Expansion part: To assess the antitumor efficacy, safety and tolerability in the experimental group of IN10018 in combination with Tislelizumab, carboplatin and etoposide as compared to the control group of Tislelizumab in combination with carboplatin and etoposide as the first-line treatment in ES-SCLC.


Recruitment information / eligibility

Status Recruiting
Enrollment 120
Est. completion date October 21, 2025
Est. primary completion date January 24, 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria 1. Male or female aged 18-75 years old at the time of signing informed consent. 2. Be able to understand and be willing to sign informed consent. 3. Histologically confirmed ES-SCLC (according to the Veterans Administration Lung Study Group (VALG) staging system), which is not suitable for locally radical therapy. 4. Has not received any systemic antitumor therapy for ES-SCLC. 5. Has at least one measurable tumor lesion per RECIST 1.1. 6. Has an ECOG performance status of 0 or 1. 7. Estimated life expectancy is more than 3 months. 8. Has adequate organ function of bone marrow, liver, kidney, and coagulation. Relative laboratory tests must be performed within 7 days prior to first dose of study treatment/randomization. 9. AEs due to prior antitumor therapy must be recovered to = Grade 1 (CTCAE v5.0) or a steady state as assessed by investigators 10. Subjects (male and female) with childbearing potential must agree to use contraception during the treatment phase and through 3 months after the last dose of study treatment. Exclusion Criteria 1. Has known active or untreated central nervous system (CNS) metastases, and/or carcinomatous meningitis. 2. Spinal cord compression without surgery and/or radiation therapy, or previously diagnosed and treated spinal cord compression without evidence that disease has been clinically stable for at least 7 days prior to the first dose of study treatment/randomization. 3. Pleural, pericardial or abdominal effusion that are clinically symptomatic and require puncture or drainage. 4. Symptomatic hypercalcemia. 5. Malignancies other than the study disease within 3 years prior to the first dose of study treatment/randomization. 6. Have received palliative radiotherapy for bone metastasis within 14 days prior to the first dose of study treatment/randomization. 7. Have had allogeneic haematopoietic stem cell transplantation or organ transplantation. 8. History of active autoimmune disease required systemic treatment (including but not limited to drugs for disease control, corticosteroids, or immunosuppressive drugs) within the past 2 years. 9. Have an immunodeficiency disorder or have received systemic steroid therapy (prednisone or equivalent corticosteroid > 10 mg/day) or other immunosuppressants within 7 days prior to the first dose of study treatment/randomization. 10. History of idiopathic pulmonary fibrosis, idiopathic pneumonia and organizing pneumonia, and interstitial pneumonitis or active pneumonia diagnosed per imaging examination at baseline. 11. Have had FAK inhibitors treatment. 12. Has a history of major cardiovascular or cerebrovascular diseases within 6 months prior to the first dose of study treatment/randomization. 13. Have malabsorption syndrome or cannot take study drugs orally. 14. Any active infection requiring systemic therapy within 14 days prior to the first dose of study treatment. 15. Active pulmonary tuberculosis 16. Human immunodeficiency virus (HIV) infection, active hepatitis B infection, or hepatitis C infection. 17. Known hypersensitivity or allergy to IN10018, anti-PD-1/L1 monoclonal antibodies, carboplatin or etoposide or to their drug components. 18. Pregnant or lactating women or are expected to be pregnant or lactating during study treatment.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
IN10018
orally taken once daily
Tislelizumab
200mg D1, Q3W, intravenously
Carboplatin
AUC 5 mg/ml/min, D1, Q3W, intravenously
Etoposide
Etoposide 100 mg/m2, D1-D3, Q3W, intravenously

Locations

Country Name City State
China Shandong Province Cancer Hospital Jinan
China Tianjin Medical University Cancer Institute & Hospital Tianjin
China Henan Provincial People's Hospital Zhengzhou

Sponsors (1)

Lead Sponsor Collaborator
InxMed (Shanghai) Co., Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary To identify the Recommended phase II dose (RP2D) of IN10018 in combination with Tislelizumab, Carboplatin and Etoposide in first-line ES-SCLC. Evaluate proportion of patients suffered with AEs defined as dose-limited toxicities (DLTs) per protocol; and RP2D will be determined per the incidence of AEs defined as DLTs. Up to 3 years
Primary Progress free survival (PFS) of IN10018 in combination with Tislelizumab, carboplatin and etoposide as compared to Tislelizumab in combination with carboplatin and etoposide in first-line ES-SCLC per BICR based on RECIST 1.1 Defined as the time from randomization to first documentation of disease progression or to death due to any cause, whichever comes first. Up to 3 years
Secondary PFS of IN10018 in combination with Tislelizumab, carboplatin and etoposide as compared to Tislelizumab in combination with carboplatin and etoposide in first-line ES-SCLC per investigator based on RECIST 1.1 Defined as the time from randomization to first documentation of disease progression or to death due to any cause, whichever comes first. Up to 3 years
Secondary Objective response rate (ORR) of IN10018 in combination with Tislelizumab, carboplatin and etoposide as compared to Tislelizumab in combination with carboplatin and etoposide in first-line ES-SCLC per BICR and investigator based on RECIST 1.1. Defined as the proportion of subjects with complete response (CR) or partial response (PR). Up to 3 years
Secondary Duration of objective response (DOR) of IN10018 in combination with Tislelizumab, carboplatin and etoposide as compared to Tislelizumab in combination with carboplatin and etoposide in first-line ES-SCLC per BICR and investigator based on RECIST 1.1. Defined as the time from start of the first documentation of CR or PR to the first documentation of disease progression or to death due to any cause, whichever comes first. Up to 3 years
Secondary Disease Control Rate (DCR) of IN10018 in combination with Tislelizumab, carboplatin and etoposide as compared to Tislelizumab in combination with carboplatin and etoposide in first-line ES-SCLC per BICR and investigator based on RECIST 1.1 Defined as the proportion of patients with CR, PR, or stable disease (SD). Up to 3 years
Secondary Overall survival (OS) of IN10018 in combination with Tislelizumab, carboplatin and etoposide as compared to Tislelizumab in combination with carboplatin and etoposide in first-line ES-SCLC. Defined as the time from randomization to the date of death due to any cause. Up to 3 years
Secondary Number of patients with adverse event The number of participants who experienced AEs is presented. Up to 3 years
Secondary PK: AUC of IN10018 following single dose administration and at steady state Area under the concentration-time curve (AUC) Up to 3 years
Secondary PK: Cmax of IN10018 following single dose administration and at steady state Maximum concentration (Cmax) Up to 3 years
Secondary PK: Ctrough of IN10018 following single dose administration and at steady state Trough concentration (Ctrough) Up to 3 years
Secondary PK: Tmax of IN10018 following single dose administration and at steady state Time to Cmax (Tmax) Up to 3 years
Secondary PK: t1/2 of IN10018 following single dose administration and at steady state Elimination half-life (t1/2) Up to 3 years
Secondary PK: CL/F of IN10018 following single dose administration and at steady state apparent clearance (CL/F) Up to 3 years
Secondary PK: Vd/F of IN10018 following single dose administration and at steady state Apparent volume of distribution (Vd/F) Up to 3 years
See also
  Status Clinical Trial Phase
Not yet recruiting NCT02179528 - Study of Small Doses of Etoposide as Maintenance Treatment in Small Cell Lung Cancer(SCLC) Phase 2
Recruiting NCT05384015 - Study of Pembrolizumab, Lenvatinib and Chemotherapy Combination in First Line Extensive-stage Small Cell Lung Cancer Phase 2
Not yet recruiting NCT05745350 - First Line Pembrolizumab, Plinabulin Plus Etoposide and Platinum (EP) for ES-SCLC Phase 2
Completed NCT03325816 - Nivolumab and 177Lu-DOTA0-Tyr3-Octreotate for Patients With Extensive-Stage Small Cell Lung Cancer Phase 1/Phase 2
Recruiting NCT05856695 - A Phase II Study Assessing the Efficacy of Etoposide Free Chemotherapy Plus Durvalumab (MEDI4736) in First Line Extensive Disease Small Cell Lung Cancer (SCLC) Phase 2
Recruiting NCT05703971 - Quaratusugene Ozeplasmid (Reqorsa) and Atezolizumab Maintenance Therapy in ES-SCLC Patients Phase 1/Phase 2
Not yet recruiting NCT06429696 - PD-L1 Inhibitor Combined With Apatinib as First-line Maintenance Treatment for Extensive-stage Small Cell Lung Cancer Phase 2
Terminated NCT00003496 - Antineoplaston Therapy in Treating Patients With Recurrent or Extensive-Stage Small Cell Lung Cancer Phase 2
Completed NCT03059667 - Immunotherapy as Second-line in Patient With Small Cell Lung Cancer Phase 2
Active, not recruiting NCT03923270 - Radiotherapy and Durvalumab/Durvalumab Combo (Tremelimumab/Olaparid) for Small Cell Lung Cancer Phase 1
Not yet recruiting NCT06348797 - Phase I Clinical Study of α-PD-L1/DLL3 CAR-T in Patients With R/R SCLC Phase 1
Active, not recruiting NCT04462276 - Thoracic RadiothErapy With Atezolizumab in Small Cell lUng canceR Extensive Disease Phase 2
Recruiting NCT05680922 - DLL3-Directed Chimeric Antigen Receptor T-cells in Subjects With Extensive Stage Small Cell Lung Cancer Phase 1
Not yet recruiting NCT04967625 - A Phase II Study of Sintilimab Combined With Anlotinib in Treatment of ED-SCLC Phase 2
Recruiting NCT04659785 - A Study of Fluzoparib Combined With Apatinib as Second-Line Treatment of Patients With Extensive Stage Small Cell Lung Cancer(FA-ES-SCLC) Phase 1/Phase 2
Active, not recruiting NCT04670445 - Improving Patient and Caregiver Understanding of Risks and Benefits of Immunotherapy for Advanced Cancer N/A
Not yet recruiting NCT05066945 - Application of ctDNA in the Evaluation of Curative Effect and Prognosis of SCLC Patients
Recruiting NCT05945745 - Molecular Analysis and Treatment Options of SCLC
Not yet recruiting NCT03755115 - SHR-1210 Combined With Epirubicin in the Treatment of Extensive Disease Small Cell Lung Cancer Phase 2
Terminated NCT05027867 - KRT-232 in Subjects With Relapsed or Refractory Small Cell Lung Cancer Phase 2